McKeown Q&A

Foley & Lardner LLP partner Jason Mehta commented on a recent health care litigation settlement with the U.S. Securities and Exchange Commission in the Clinical Trials Arena article, “Cassava Sciences: Phase III trials storm ahead amid controversy.”

Foley & Lardner LLP special counsel John Strom shared insight on the potential impact of the BIOSECURE ACT in the BioSpaces article, "WuXi Biologics Faces Uncertain Future in the U.S. After BIOSECURE Blow."

Foley & Lardner LLP partner Anil Shankar offered insight on California's Proposition 34, a ballot measure this election season, in the KCRW article, "Confused on Prop 34? It’s about the politics of rent control."